智翔金泰去年亏损超5亿元

Group 1 - The core viewpoint of the news is that Zhixiang Jintai has been consistently operating at a loss since its establishment, with significant losses reported in recent years, indicating challenges in achieving profitability [2] - For the fiscal year 2025, Zhixiang Jintai reported an operating revenue of 231 million yuan, a substantial increase of 666.65% year-on-year, while the net profit attributable to shareholders was a loss of 536 million yuan, which is a 32.74% improvement compared to the previous year [1] - The company's total assets at the end of the reporting period were approximately 2.99 billion yuan, reflecting a decrease of 4.87% year-on-year, and the equity attributable to shareholders decreased by 25.49% to approximately 1.58 billion yuan [1] Group 2 - The significant revenue growth is attributed to the market expansion of the company's first commercial product, the monoclonal antibody injection, and substantial licensing income from the GR1803 injection commercialization agreement, positively impacting the net profit for the period [1] - Zhixiang Jintai has been in a loss-making state since its inception in 2015, with net profits for the years 2019 to 2024 recorded as -158 million yuan, -373 million yuan, -322 million yuan, -576 million yuan, -801 million yuan, and -797 million yuan respectively, indicating a trend of increasing losses [2]